Introduction

Cerebrotendinous xanthomatosis (CTX) is a rare inherited disorder of lipid metabolism that often goes unrecognised for years. This condition, caused by mutations in the CYP27A1 gene, disrupts bile acid synthesis, resulting in an abnormal accumulation of toxic sterol metabolites throughout the body. Tragically, many patients are diagnosed only after severe neurological and systemic symptoms have developed. 

The good news: CTX is treatable; the earlier it's detected, the better the outcome. This has pushed clinicians and scientists to prioritise sensitive, accessible biomarkers in plasma and cerebrospinal fluid (CSF) for the earliest possible diagnosis.

This article provides an up-to-date, real-world overview of established and emerging plasma and CSF biomarkers for early CTX detection. We will cover their strengths, weaknesses, and prospects, grounded in how these tests affect patients’ lives.¹

Pathophysiology and the need for biomarkers

CTX is driven by mutations in the CYP27A1 gene encoding sterol 27-hydroxylase, an enzyme crucial to bile acid synthesis. When this enzyme fails, the body is unable to produce chenodeoxycholic acid efficiently. As a result, cholesterol is shunted into the production of cholestanol and unusual bile alcohols, which build up in the brain, eyes, tendons, and elsewhere, causing:

• Early-onset cataracts
• Chronic diarrhea
• Tendon xanthomas
• Neurologic regression
• Psychiatric symptoms
• Premature atherosclerosis

As the symptoms overlap with common disorders, CTX can evade detection for years. Reliable blood and CSF biomarkers unlock the possibility of catching and treating the disease early.²

Plasma biomarkers for CTX

Plasma cholestanol: the gold standard

• Cholestanol is the most sensitive and specific plasma biomarker for CTX
• CTX patients show cholestanol levels many times above normal; even mildly elevated levels in this context may signal CTX
• Diagnostic threshold: CTX is very likely if clinical suspicion exists and plasma cholestanol is greater than6–8 μg/mL
• Testing method: typically gas chromatography-mass spectrometry (GC-MS)
• Mild increases in cholestanol levels may also be seen in rare liver disorders, so context is vital

Plasma bile alcohols: a valuable supplement

• Numerous abnormal bile alcohols accumulate in CTX, often visible in blood, urine, or bile
• Elevated bile alcohol glucuronides are highly suggestive of CTX, especially useful in ambiguous cases and family screening
• Less available and less standardised than cholestanol in many clinical laboratories

7α-hydroxy-4-cholesten-3-one (C4)

• Indirect marker of disrupted cholesterol metabolism
• Often elevated in CTX, but not specific, it can also signal other liver and metabolic disorders
• Best used as a secondary diagnostic marker

Plasma cholesterol and lipoproteins

• Usually normal or only mildly elevated in CTX patients
• Lipoprotein subfractions (LDL, HDL) are not helpful for diagnosis

Cerebrospinal fluid (CSF) biomarkers

CSF cholestanol

• CSF cholestanol is universally increased in neurologically affected CTX patients
• Reflects the degree of central nervous system (CNS) involvement
• Helpful in monitoring neurological disease progression and treatment effects

Brain-specific proteins (NfL & Tau)

• CSF neurofilament light chain (NfL) and tau protein are markers of ongoing neurodegeneration
• It is not specific to CTX but may help monitor CNS injuries

Bile alcohols in CSF

• Abnormal bile alcohols are often increased in the CSF of CTX patients, underscoring disturbed sterol trafficking across the blood-brain barrier.

Emerging and experimental biomarkers

Metabolomic signatures

• Modern “metabolomics” technology can now profile unique sterol and bile acid patterns specific to CTX
• It may help diagnose milder or atypical forms that evade standard testing³

Genetic testing

• Sequencing the CYP27A1 gene confirms diagnosis and guides family screening
• Gene-based data can correlate enzyme activity and biomarker patterns, offering clues to severity

The role of biomarkers in early (preclinical) diagnosis

Why early matters

Neurological damage in CTX often cannot be reversed. However, early intervention with chenodeoxycholic acid can prevent or reverse some non-neurologic symptoms and stabilise patients.⁴

Early diagnosis makes a difference

• Prevents irreversible harm: Early detection avoids lifelong disability
• Facilitates family screening: Helps find affected relatives before symptoms develop

Biomarker-driven early detection

• Elevated plasma cholestanol in an at-risk but asymptomatic individual is reason enough to start treatment
• Newborn screening using dried blood spots (cholestanol, bile alcohols + genetic sequencing) is under investigation and holds promise for earlier population detection

Comparison table: plasma vs CSF biomarkers in CTX

Real-world diagnostic approach

A practical, stepwise approach to CTX testing:

Suspect CTX

In patients with unexplained juvenile cataracts, neurologic symptoms, persistent diarrhoea, or tendon xanthomas.

Measure plasma cholestanol 

A marked elevation supports the diagnosis.

Check plasma bile alcohols 

If available, use for confirmation.

Sequence CYP27A1 

Provides definitive diagnosis and guides family screening.

Reserve CSF tests 

For neurological assessment or clinical research.

Screen relatives 

Using biochemical and genetic results.⁸

Recent results and advances

• Cholestanol levels greater than 6–8 μg/mL with supportive features strongly suggest CTX⁹
• Newborn screening (bloodspot methods + genetics) is increasingly validated and could enable widespread pre-symptomatic identification
• Metabolomics is uncovering new markers such as trihydroxycholestanoic acid that may further push the boundaries of early CTX detection
• Treatment monitoring: Falling cholestanol (plasma and CSF) levels with therapy parallel clinical stabilisation

Human and ethical dimensions

Reduced “diagnostic odyssey” 

Reliable biomarkers cut years off the time to correct CTX diagnosis, transforming lives.

Advocacy impact 

Patient groups push for accessible testing worldwide.

Awareness 

Targeted education for paediatricians, neurologists, and ophthalmologists is crucial so CTX is not missed.

Frequently asked questions (FAQs)

What is the first test I should order if I suspect CTX?

Plasma cholestanol is most useful. An isolated elevation, in the proper clinical context, strongly correlates with CTX.

Is genetic testing required for diagnosis?

Yes, CYP27A1 sequencing confirms CTX and helps screen relatives who may also be affected.

Can CTX be detected in newborns?

Yes! Pilot newborn screening programs measure cholestanol and bile alcohols in dried blood spots and can include genetic testing, allowing pre-symptomatic detection.

How do treatment and monitoring work?

Chenodeoxycholic acid treatment reduces cholestanol levels (in plasma and CSF) and halts disease progression, particularly if started early.

Are plasma and CSF cholestanol tests widely available?

Plasma cholestanol testing via GC-MS is increasingly common, while CSF tests are limited to specialised settings.

How specific is a high cholestanol level?

Very specific for CTX, if clinical findings fit, but rare liver disorders may also raise cholestanol.

Summary

Thanks to advances in plasma and CSF biomarkers, early, noninvasive detection of CTX is now a reality. Plasma cholestanol remains the most reliable, accessible tool, but the addition of bile alcohols, metabolomics, and genetic testing increasingly expands the early diagnostic window, even into the newborn period. CSF markers enrich our understanding of neurological involvement but are used mainly within specialised situations. Raising clinician awareness, reducing testing barriers, and supporting patient advocacy remain as important as scientific innovation in changing the lives of those with CTX.